InflaRx N.V. (IFRX) vs Inhibikase Therapeutics, Inc. (IKT)
InflaRx N.V. and Inhibikase Therapeutics, Inc. are both Biotechnology companies. InflaRx N.V. and Inhibikase Therapeutics, Inc. are of similar size ($293.0M and $284.4M). Inhibikase Therapeutics, Inc. grew revenue faster over the last twelve months: 110.9% against −83.4%. Across the 12 metrics below, Inhibikase Therapeutics, Inc. leads on 8 and InflaRx N.V. on 4.
Valuation
Profitability
| Metric | IFRX | IKT | Biotechnology median |
|---|---|---|---|
| Gross margin | (26,762.42%) | 100.00% | 65.16% |
| Operating margin | 0.00% | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% | 0.00% |
| Free cash flow margin | 0.00% | 0.00% | 0.00% |
| Return on equity | (38.71%) | (51.96%) | (57.72%) |
| Return on assets | (32.75%) | (48.04%) | (49.22%) |
| Return on invested capital | 0.00% | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack